{"entity":{"id":"hmox1","kind":"target","name":"HMOX1","aka":["heme oxygenase 1","Heme oxygenase 1","bK286B10","HO-1"],"tldr":"HMOX1 (Heme oxygenase 1) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Renal cell carcinoma.","summary":"Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Affords protection against programmed cell death and this cytoprotective effect relies on its ability to catabolise free heme and prevent it from sensitising cells to undergo apoptosis. Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 2 variants, naming Sorafenib and Sunitinib.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:5013","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5013"},{"label":"UniProt P09601","url":"https://www.uniprot.org/uniprotkb/P09601/entry"},{"label":"NCBI Gene 3162","url":"https://www.ncbi.nlm.nih.gov/gene/3162"},{"label":"Ensembl ENSG00000100292","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100292"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"HMOX1","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:5013","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5013","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P09601","url":"https://www.uniprot.org/uniprotkb/P09601/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene HMOX1","url":"https://civicdb.org/features/2657","note":"1 evidence items, 0 assertions, 2 variants; diseases: Renal Cell Carcinoma (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA HMOX1: RNA tissue enriched (lymphoid tissue 740 nTPM); blood lineage lineage enriched (monocytes 331 nTPM); high antibody staining in 6 normal tissues; highest cancer staining urothelial cancer (1 of 10 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Renal cell carcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas HMOX1 tissue","url":"https://www.proteinatlas.org/ENSG00000100292-HMOX1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000100292 associations","url":"https://platform.opentargets.org/target/ENSG00000100292/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:5013","ensembl":"ENSG00000100292","uniprot":"P09601","entrez":"3162","firstDescribed":1988,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Yoshida et al, Eur. J. Biochem, 1988, \"Human heme oxygenase cDNA and induction of its mRNA by hemin\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/3345742/","biology":"Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Affords protection against programmed cell death and this cytoprotective effect relies on its ability to catabolise free heme and prevent it from sensitising cells to undergo apoptosis. Catalyses the oxidative cleavage of heme at the alpha-methene bridge carbon, released as carbon monoxide (CO), to generate biliverdin IXalpha, while releasing the central heme iron chelate as ferrous iron. Location: Endoplasmic reticulum membrane (UniProt). Locus 22q12.3 (HGNC).","whereFound":["Renal cell carcinoma: CIViC evidence names this disease"],"targetClass":"enzyme","prevalence":[]},"route":"/targets/hmox1/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}]}}